New blood test could spot key mutations in prostate cancer when tissue is scarce
NCT ID NCT06762379
First seen Apr 03, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study aims to validate a new liquid biopsy (blood test) algorithm for detecting HRR gene mutations in patients with metastatic prostate cancer whose tumor tissue is not available or suitable for testing. The approach could help more patients access targeted therapies. Researchers will enroll 125 participants to confirm the test's accuracy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER (MPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
European Institute of oncology
RECRUITINGMilan, Italy, 20141, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.